Sopharma Acquires 90% of The Capital of Serbian Ivanchich and sons

Sopharma (

) has sealed the deal for the acquisition of 90% of the capital of Serbian Ivanchich and sons, x3news reported.

The construction of a new medical plant is expected to start by 2009. The Belgrade company currently has 21 products on its production list.

The investment will cost around 8 mln euros. The new plant will create 120 jobs.

We remind that in mid-December the Ukrainian Commission for Protection of Competition allowed Sopharma to acquire a little over 50% of the capital of OAO Vitamini, thus gaining control of the company.

In November 2007 Sopharma's Board of Directors decided to acquire the Ukrainian company, as well as a Romanian peer.

Sopharma's stock lost 4.15% today to an average of 6.23 leva apiece at a turnover of 24,249 shares. There are 50 bids placed between 5.53 and 6.16 leva and 80 asks ranging from 6.23 to 7.13 leva.